{
    "clinical_study": {
        "@rank": "158176", 
        "arm_group": [
            {
                "arm_group_label": "Part 1: Methadone + DCV 3DAA FDC + BMS-791325", 
                "arm_group_type": "Experimental", 
                "description": "Methadone 40-120 mg tablet or solution orally once on Day 1\nMethadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
            }, 
            {
                "arm_group_label": "Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325", 
                "arm_group_type": "Active Comparator", 
                "description": "Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1\nBuprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once +  DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effects of steady state DCV/ASV/BMS-791325 fixed\n      dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of Methadone in\n      subjects with the stable dose of Methadone and on the PK of Buprenorphine in subjects with\n      the stable dose of Buprenorphine."
        }, 
        "brief_title": "Drug Interaction & Methadone & Buprenorphine", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "IND number: 101,943\n\n      Primary purpose: Other: Phase 1 Clinical Pharmacology drug interaction study in healthy\n      subjects"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Subject must be on stable Methadone or Buprenorphine regimens  for at least 28 days\n             prior to screening\n\n        Exclusion Criteria:\n\n          -  Subjects must be healthy except for history of Methadone or Buprenorphine treatment\n             regimens\n\n          -  Prior exposure to DCV, ASV or BMS-791325 within 3 months of screening or any other\n             investigational drug or placebo within 4 weeks of study drug administration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02045693", 
            "org_study_id": "AI443-108"
        }, 
        "intervention": [
            {
                "arm_group_label": "Part 1: Methadone + DCV 3DAA FDC + BMS-791325", 
                "intervention_name": "Methadone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 1: Methadone + DCV 3DAA FDC + BMS-791325", 
                    "Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325"
                ], 
                "intervention_name": "DCV 3DAA FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 1: Methadone + DCV 3DAA FDC + BMS-791325", 
                    "Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325"
                ], 
                "intervention_name": "BMS-791325", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325", 
                "intervention_name": "Buprenorphine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325", 
                "intervention_name": "Naloxone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Methadone", 
                "Naloxone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 24, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase1, Open-Label, Drug-Drug Interaction Study Between Methadone and Daclatasvir/Asunaprevir/BMS-791325 3 DAA FDC + 75mg BMS-791325 and Between Buprenorphine/Naloxone and Daclatasvir/Asunaprevir/BMS-791325 3 DAA FDC +75mg BMS-791325", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed concentration (Cmax) of R-Methadone for Part 1", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to Day 13"
            }, 
            {
                "measure": "Area under the concentration-time curve in one dosing interval (AUC(TAU)) of R-Methadone for Part 1", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to Day 13"
            }, 
            {
                "measure": "Cmax of Buprenorphine and Norbuprenorphine  for Part 2", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to Day 13"
            }, 
            {
                "measure": "AUC(TAU) of Buprenorphine and Norbuprenorphine  for Part 2", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to Day 13"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02045693"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax of S-Methadone and Total Methadone for Part 1", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 13 days"
            }, 
            {
                "measure": "AUC(TAU) of S-Methadone and Total Methadone for Part 1", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 13 days"
            }, 
            {
                "measure": "Concentration at 24 hours (C24) of S-Methadone, Total Methadone and R-Methadone for Part 1", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 13 days"
            }, 
            {
                "measure": "Time of maximum observed concentration (Tmax) of S-Methadone, Total Methadone and R-Methadone for Part 1", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 13 days"
            }, 
            {
                "measure": "C24 of Buprenorphine and Norbuprenorphine  for Part 2", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 13 days"
            }, 
            {
                "measure": "Tmax of Buprenorphine and Norbuprenorphine for Part 2", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 13 days"
            }, 
            {
                "measure": "Ratio of metabolite AUC(TAU) to parent AUC(TAU) (MR_AUC(TAU)) of Norbuprenorphine to Buprenorphine", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 13 days"
            }, 
            {
                "measure": "Cmax of of Daclatasvir (DCV) , Asunaprevir (ASV) , BMS-791325, and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "10 timepoints on Day 12"
            }, 
            {
                "measure": "AUC(TAU) of DCV, ASV, BMS-791325, and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "10 timepoints on Day 12"
            }, 
            {
                "measure": "Concentration at 12 hours (C12) of DCV, ASV, BMS-791325, and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "10 timepoints on Day 12"
            }, 
            {
                "measure": "Tmax of DCV, ASV, BMS-791325, and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "10 timepoints on Day 12"
            }, 
            {
                "measure": "MR_AUC(TAU) for BMS-794712 to BMS-791325", 
                "safety_issue": "No", 
                "time_frame": "10 timepoints on Day 12"
            }, 
            {
                "measure": "Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), death and AEs leading to discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 13"
            }, 
            {
                "measure": "Results of vital signs, Electrocardiograms (ECGs), Physical Examinations (PEs) and clinical labs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 13"
            }, 
            {
                "measure": "Scores of Clinical Opiate Withdrawal Scale (COWS), Subjective Opiate Withdrawal Scale (SOWS), Objective Opiate Withdrawal Scale (OOWS), and Opiate Overdose Assessment (OOA)", 
                "safety_issue": "No", 
                "time_frame": "Up to day 13"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}